Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors
about
Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker AssessmentMolecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway BlockadeMechanisms of action of therapeutic antibodies for cancerInsulin/Insulin-like growth factors in cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and new blocking strategies.The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin ReceptorFunctional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonistCotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination StudiesInsulin-like growth factor axis targeting in cancer and tumour angiogenesis - the missing link.Insulin Receptor Isoforms in Physiology and Disease: An Updated View.Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies.Revisiting the IGF-1R as a breast cancer target.A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells.
P2860
Q26798408-B56CABEE-7E90-47FA-9052-9159B4E7132AQ28088432-F11C266F-5E64-4843-95DB-376A46A3B2AEQ28385366-3212CCE4-003C-4CA9-8655-BC4E8878B9C8Q35037802-AECB49AF-A54E-46DF-BBEF-1ADCD5324BDDQ35609517-806C1BAB-49A1-4101-81C8-09CAC02A0E85Q35894540-84CB46B2-8F18-4C8C-AB31-4ACBEAEB0879Q36387216-EB0085F1-86F2-4D29-A7C4-78EF46FD1B6DQ36930975-EE258B62-D08C-45BF-869B-BAFFC5D9368BQ37570653-315AC61D-27BC-4A9B-A81E-2166A3A95679Q38641329-477401B7-B35D-4178-B91D-F689147ACE7CQ38990201-D64C90DD-DA21-4C33-9276-63B9DF49EF51Q47668280-ED19DFD4-3F8D-4034-A672-1C72B9231D35Q51650705-A9E08FD4-B694-4E23-B717-A8BC94FB30AAQ52686152-1CEE04F8-0FA1-4A37-89A3-7B074C3C26BCQ55128069-0BB4D802-A166-48B3-9AE6-3612C4B02BC8
P2860
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase I dose-escalation study ...... nts with advanced solid tumors
@ast
Phase I dose-escalation study ...... nts with advanced solid tumors
@en
type
label
Phase I dose-escalation study ...... nts with advanced solid tumors
@ast
Phase I dose-escalation study ...... nts with advanced solid tumors
@en
prefLabel
Phase I dose-escalation study ...... nts with advanced solid tumors
@ast
Phase I dose-escalation study ...... nts with advanced solid tumors
@en
P2093
P2860
P1476
Phase I dose-escalation study ...... nts with advanced solid tumors
@en
P2093
Donald Northfelt
Elizabeth R Plimack
Jaye Viner
Jennifer McDevitt
Jiaqi Huang
Jonathan Rosenberg
Michael Menefee
Patricia Burke
Patricia LoRusso
P2860
P304
P356
10.1158/1078-0432.CCR-14-0114
P407
P50
P577
2014-07-14T00:00:00Z